Preparation and characterization of co-grinded mixtures of aceclofenac and neusilin US2 for dissolution enhancement of aceclofenac

AAPS PharmSciTech

Volumn 10, Issue 2, 2009, Pages 606-614

  Vadher, Ambarish H ^a,b,c   Parikh, Jolly R ^a   Parikh, Rajesh H ^d   Solanki, Ajay B ^a  

^a AR Patel and GH Patel Institute of Pharmacy   (India)

^b Institute of Science and Technology for Advanced Studies and Research   (India)

^c Alembic Research Centre   (India)

^d CHAROTAR UNIVERSITY OF SCIENCE AND TECHNOLOGY   (India)

Author keywords

Aceclofenac; Co grinding; Dissolution; Neusilin US2; Porous carrier

Indexed keywords

ACECLOFENAC; ATTAPULGITE; DRUG CARRIER; NEUSILIN US2; UNCLASSIFIED DRUG; ALUMINUM SILICATE; DICLOFENAC; DRUG DERIVATIVE; EXCIPIENT; MAGNESIUM; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG GRANULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; IN VITRO STUDY; INFRARED SPECTROSCOPY; X RAY POWDER DIFFRACTION; CHEMISTRY; COMPARATIVE STUDY; HYDROGEN BOND; SOLUBILITY; X RAY DIFFRACTION;

ALUMINUM SILICATES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALORIMETRY, DIFFERENTIAL SCANNING; DICLOFENAC; DRUG CARRIERS; DRUG STABILITY; EXCIPIENTS; HYDROGEN BONDING; MAGNESIUM; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; X-RAY DIFFRACTION;

EID: 67549096885     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-009-9221-6     Document Type: Article

References (48)

1. Gupta MK. Factors influencing the release of poorly-water soluble drugs from solid dispersion granules during storage, PhD Dissertation, 2002; University of Connecticut.
2. Bogner RH, Bahl D. Amorphization of Indomethacin by Co-grinding with Neusilin US2: Amorphization kinetics, Physical stability and mechanism. Pharm Res. 2006;23(10):2317-25.
3. Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals. Pharm Res. 2000;17:397-404.
4. Gupta MK, Goldman D, Bogner RH, Tseng YC. Enhanced drug dissolution and bulk properties of solid dispersions granulated with a surface adsorbent. Pharm Technol. 2001;6:563-72.
5. Gupta MK, Goldman D, Bogner RH, Tseng YC. Mechanism for further enhancement in drug dissolution from solid-dispersions granules upon storage. Pharm Dev Technol. 2002;7:103-12.
6. Gupta MK, Vanwert A, Bogner RH. Formation of physically stable amorphous drugs by milling with Neusilin. J Pharm Sci. 2003;92:502-17.
7. Watanabe T, Wakiyama N, Usui F, Ikeda M, Isobe T, Senna M. Stability of amorphous indomethacin compounded with silica. Int J Pharm. 2001;226:81-91.
8. Watanabe T, Wakiyama N, Hasegawa S, Kusai A, Senna M. Prediction of apparent equilibrium solubility of indomethacin compounded with silica by C13 solid state NMR. Int J Pharm. 2002;248:123-9.
9. Fujii M, Okada H, Shibata Y, Teramachi H, Kondoh M, Watanabe Y. Preparation, characterization, and tabletting of a solid dispersion of indomethacin with crospovidone. Int J Pharm. 2005;293:145-53.
10. Watanabe T, Wakiyama N, Hasegawa S, Kusai A, Senna M. Comparison of polyvinylpyrrolidone and silica nanoparticles as carriers for indomethacin in a solid state dispersion. Int J Pharm. 2003;250:283-6.
11. Otsuka M, Matsumoto T, Kaneniwa N. Effect of environmental temperature on polymorphic solid-state transformation of indomethacin during grinding. Chem Pharm Bull. 1986;34:1784-93.
12. Ali AS, Yamamoto K, El-sayed AM, Habib FS, Nakai Y. Molecular behavior of flufenamic acid in physical and ground mixtures with florite. Chem Pharm Bull. 1992;40:1289-94.
13. Nakai Y, Fukuoka E, Nakajima S, Iida Y. Effect of grinding on physical and chemical properties of crystalline medicinals with microcrystalline cellulose. II. Retention of volatile medicinals in ground mixture. Chem Pharm Bull. 1978;26:2983-89.
14. Kaneniwa N, Ikekawa A, Sumi M. A decrease in crystallinity of Amobarbital by mechanical treatment in the presence of the diluents. Chem Pharm Bull. 1978;26:2734-43.
15. Kinoshita M, Baba K, Nagayasu A, Yamabe K, Shimooka T. Improvement of solubility and oral bioavailability of a poorly water-soluble drug, TAS-301, by its melt-adsorption on a porous calcium silicate. J Pharm Sci. 1997;91:362-70.
16. Friedrich H, Nada A, Roland B. Solid state and dissolution rate characterization of co-ground mixtures of nifedipine and hydrophilic carriers. Drug Dev Ind Pharm. 2005;31(8):719-28.
17. Chuang IS, Maciel GE. Probing hydrogen bonding and the local environment of silanols on silica surfaces via nuclear spin cross polarization dynamics. Phys Chem B. 1996;101:401-6.
18. Chuang IS, Maciel GE. A detailed model of local structure and silanol hydrogen bonding of silica gel surfaces. J Phys Chem B. 1997;101:3052-64.
19. Fuji C. Company Literature on Neusilin, Fuji Chemical Industry, Toyama, Japan; 1997.
20. Zawilla NH, Mohammad MAA, El Kousy NM, El-Moghazy Aly SM. Determination of aceclofenac in bulk and pharmaceutical formulations. J Pharm Biomed Anal. 2002;27:243-51.
21. The British Pharmacopoeia 1999:34.
22. Buckton G, Choularton A, Beezer AE, Chaltham SM. The effect of the comminution technique on the surface energy of a powder. Int J Pharm. 1988;47:121-8.
23. Kitamura S, Miyamae A, Koda S, Morimoto Y. Effect of grinding on the solid-state stability of cefixime trihydrate. Int J Pharm. 1989;56:125-34.
24. Otsuka M, Ofus T, Matsuda Y. Effect of environmental humidity on the transformation pathway of carbamezepine polymorphic modifications during grinding. Colloids Surf B. 1999;13:263-73.
25. Ferraz HG, Carpentieri LN, Watanabe SP. Dissolution profile evaluation of solid pharmaceutical forms containing chloramphenicol marketed in Brazil. Braz Arch Biol Technol. 2007;50(1):57-65.
26. Feng T, Pinal R, Carvajal MT. Process induced disorder in crystalline materials: Differentiating defective crystals from the amorphous form of griseofulvin. J Pharm Sci. 2008;97(8):3207-21.
27. Lian Y. Amorphous pharmaceutical solids: Preparation, characterization and stabilization. Adv Drug Del Rev. 2001;48:27-42.
28. Gusseme D, Neves C, Willart JF, Rameau A, Descamps M. Ordering and disordering of molecular solids upon mechanical milling: The case of fananserine. J Pharm Sci. 2008;97(8):5000-12.
29. Brand B. Polymorphic transitions of cimetidine during manufacture of solid dosageforms. Int J Pharm. 1996;140:195-206.
30. Desprez S, Descamps M. Transformations of glassy indomethacin induced by ball-milling. J Non-Cryst Solids. 2006;352:4480-5.
31. Descamps M, Willart JF, Dudognon E, Caron V. Transformation of pharmaceutical compounds upon milling and comilling: The role of Tg. J Pharm Sci. 2007:96:1398-407.
32. Caron V, Willart JF, Danede F, Descamps M. The implication of the glass transition in the formation of trehalose/mannitol molecular alloys by ball milling. Solid State Commun. 2007;144:288-92.
33. Tsukushi I, Yamamuro O, Matsuo T. Solid state amorphization of organic molecular crystals using a vibrating mill. Solid State Commun. 1995;94:1013-18.
34. Lee B, Jung H. Enhanced bioavailability of poorly water-soluble aceclofenac using PEG-based solid dispersion in rats, beagle dogs and human subjects. AAPS Annual Meeting, New Orleans, LA, USA. Pharm Sci Supplement. 1999;1(4):S614-614 November 14-18.
35. Kim T, Shin J, Lee B. Enhanced dissolution and bioavailability of poorly water-soluble aceclofenac using solid dispersion system. Denver, Colorado, USA: AAPS, Annual Meeting; 2001 October 21-25.
36. Patel AR, Joshi VY. Evaluation of SLS: APG mixed surfactant systems as carrier for solid dispersion. AAPS PharmSciTech. 2008;9(2):583-90.
37. Mutalik S, Anju P, Manoj K, Usha AN. Enhancement of dissolution rate and bioavailability of aceclofenac: A chitosan-based solvent change approach. Int J Pharm. 2008;28:350(1-2):279-90.
38. Usha AN, Mutalik S, Reddy MS, Ranjith AK, Kushtagi P, Udupa N. Preparation and, in vitro, preclinical and clinical studies of aceclofenac spherical agglomerates. Eur J Pharm Biopharm. 2008;70(2):674-83.
39. Dahiya S, Pathak K. Physicochemical characterization and dissolution enhancement of aceclofenac-hydroxypropyl beta-cyclodextrin binary systems. PDA J Pharm Sci Technol. 2006;60(6):378-88.
40. Konno T, Kinuno K, Kataoka K. Physical and chemical changes of medicinals in mixtures with adsorbents in the solid state. I. Effect of vapor pressure of the medicinals on changes in crystalline properties. Chem Pharm Bull. 1986;34:301-7.
41. Kim KH, Frank MJ, Henderson NL. Application of differential scanning calorimetery to the study of solid drug dispersions. J Pharm Sci. 1985;74:283-9.
42. Oguchi T. Improved dissolution of naproxen from solid dispersions with porous additives. Yakuzaigaku 1997;57:168-73.
43. Sharma S, Sher P, Badve S, Pawar AP. Adsorption of meloxicam on porous calcium silicate: Characterization and tablet formulation. AAPS PharmSciTech. 2005;6(4):ARticle 76
44. Byrne RS, Deasy PB. Use of commercial porous ceramic particles for sustained drug delivery. Int J Pharm. 2002;246:61-73.
45. Watanabe T, Hasegawa S, Wakiyama N, Usui F, Kusai A. Solid state radical recombination and charge transfer across the boundary between indomethacin and silica under mechanical stress. J Solid State Chem. 2002;164:27-33.
46. Tong P, Taylor LS, Zografi G. Influence of alkali metal counterions on the glass transition temperature of amorphous indomethacin salts. Pharm Res. 2002;19:629-54.
47. Tong P, Zografi G. Solid-state characteristics of amorphous sodium indomethacin relative to its free acid. Pharm Res. 1999;16:1186-92.
48. Watanabe T, Ohno I, Wakiyama N, Kusai A, Senna M. Stabilization of amorphous indomethacin by co-grinding in a ternary mixture. Int J Pharm. 2002;241:103-11.